Investor Ideas Adds New #Stocks in #Biotech, #Tech and #Mining; (NasdaqGM: $EIGR), (NasdaqGM: $APEN), (NasdaqGM: $PRTK), (NasdaqGS: $CASA), (TSX: $BSR.V)
Point Roberts, WA and Delta, BC - January 19, 2018 (Investorideas.com Newswire) Investorideas.com, a global news source and leading investor resource covering actively traded sectors announces this week's additions to its global stock directories in biotech, tech and mining.
Investorideas.com tracks companies in high-profile trading sectors and makes ongoing additions to its stock directories for its members. Free previews of all directories are available to the public with full login access only accessible to members.
The newest biotech additions are all Nasdaq-listed and include a biopharma company with drug development for orphan diseases, a medical device company targeting obesity and Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK), which is crossing over in to the biodefense sector of homeland defense with its antibiotic - omadacycline.
The latest tech companies are involved in the wireless and Artificial Intelligence (AI) sectors, while the newest mining company is involved in gold mining and geothermal projects in Guatemala.
New Biotech Companies Added:
Eiger BioPharmaceuticals, Inc. (NasdaqGM:EIGR) is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for orphan diseases. We are committed to translational innovation and developing well-characterized drugs acting on newly identified or novel, validated targets. Our mission is to systematically reduce the time and cost of the drug development process to more rapidly deliver important medicines to patients with orphan diseases.
Apollo Endosurgery, Inc. (NasdaqGM:APEN) is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo's device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 80 countries today.
Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. The Company's lead product candidate, omadacycline, is a new, once-daily oral and intravenous broad-spectrum antibiotic being developed for the treatment of serious community-acquired bacterial infections, including community-acquired bacterial pneumonia (CABP), acute bacterial skin and skin structure infections (ABSSSI), and urinary tract infections. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications of ABSSSI, CABP, uUTI and cUTI. Paratek has completed Phase 3 development activities for omadacycline in CABP and ABSSSI and has initiated its New Drug Application to the U.S. FDA in the United States. Paratek has licensed rights for omadacycline to Zai Lab for the greater China region, and retains all remaining global rights. Under a research agreement with the U.S. Department of Defense, omadacycline also is being studied against pathogenic agents causing infectious diseases of public health and biodefense importance, including plague and anthrax. Paratek's second Phase 3 product candidate, Seysara™ (sarecycline), is being developed by Allergan in the U.S. as a new once-daily oral therapy for the treatment of acne. Allergan has completed Phase 3 development activities for Seysara and its new drug application was accepted for review by the U.S. Food and Drug Administration in December 2017. Paratek retains all ex-U.S. rights to Seysara.
New Tech Companies Added:
Casa Systems, Inc. (NasdaqGS:CASA) provides software solutions that enable cable, wireless and wireline broadband providers to meet the growing demand for gigabit bandwidth and services. We provide a suite of software-centric infrastructure solutions that allow cable service providers to deliver voice, video and data services over a single platform at multi-gigabit speeds. In addition, we offer solutions for next-generation distributed and virtualized architectures in cable operator, fixed telecom and wireless networks. Our solutions are commercially deployed in over 70 countries serving more than 400 customers, including regional service providers as well as some of the world's largest Tier 1 broadband service providers.
GWG Holdings, Inc. (NasdaqCM:GWGH), the parent company of GWG Life and Life Epigenetics, is a financial services company committed to transforming the life insurance industry through disruptive and innovative products and services. GWG Life is developing a suite of new longevity-based products for consumers and financial advisors under the LifeCare Xchange (LCX) platform that provides consumers owning life insurance the opportunity to exchange their policies for products that can be used to pay for long-term care and other retirement financial needs. Life Epigenetics seeks to further transform the industry by applying proprietary M-Panel epigenetic technology to disrupt traditional life insurance underwriting practices. AI: January 2018 - Dr. Olson will bring machine learning, artificial intelligence and advanced data science to the company's epigenetic technology that promises to be transformational to life insurance underwriting.
New Mining Companies Added
Bluestone Resources Inc. (TSX: BSR.V) is a mineral exploration and development company that is focused on advancing its 100% owned Cerro Blanco gold and Mita geothermal projects located in Guatemala. The Cerro Blanco Project economics, as disclosed in the Company's Cerro Blanco Preliminary Economic Assessment which is available at www.sedar.com, and updated mineral resource estimate for Cerro Blanco indicates a robust project with an expected nine-year mine life producing 952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital expenditures estimated in the PEA to fund construction and commissioning is estimated at US$170.8 million with all-in sustaining cash costs (as defined per World Gold Council guidelines, less corporate general and administration costs) estimated to be US$490 per ounce of gold produced.
The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.
About Investorideas.com - News that Inspires Big Ideas
www.Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors. Sectors we cover include tech (AI, drones, internet of things) , payments, crypto and blockchain, biotech, mining, energy, renewable energy, water , marijuana and hemp stocks, food and beverage, defense and security (biometrics/cyber) ,Latin America, sports, entertainment, luxury brands and gaming.
The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 14 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Investor Ideas Stock Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more - use our stock directories and access them online 24/7 with login as a member to find your next big idea!
Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp
Investorideas.com is also a CSE service provider: http://thecse.com/en/services/services-for-listed-companies
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.